Table 3.
Men | Women | |||||
---|---|---|---|---|---|---|
β | p | AOR (95% CI)* | β | p | AOR (95% CI)* | |
Disordered opiate use | ||||||
CA | ||||||
None** | - | - | - | - | - | - |
1–2 types | 2.76 | 0.015 | 15.84 (1.72–145.45) | 2.16 | 0.082 | 8.70 (0.76–99.99) |
3 or more types | 2.97 | 0.015 | 19.49 (1.82–208.29) | **** | **** | **** |
Minor stressors | ||||||
None** | - | - | - | - | - | - |
1 to 2 | 2.67 | 0.015 | 14.41 (1.73–120.45) | 2.20 | 0.040 | 9.03 (1.11–73.55) |
3 or more | 3.10 | 0.006 | 22.23 (2.57–192.40) | 3.32 | 0.003 | 27.75 (3.22–239.33) |
Χ24 (p value)*** | 6.17 | 0.187 | 79.29 | <0.001 | ||
Disordered cannabis use | ||||||
CA | ||||||
None** | - | - | - | - | - | - |
1–2 types | 0.65 | 0.123 | 1.92 (0.83–4.42) | 2.83 | 0.014 | 16.94 (1.82–157.54) |
3 or more types | 1.22 | 0.043 | 3.40 (1.04–11.10) | 2.71 | 0.045 | 15.03 (1.07–211.66) |
Minor stressors | ||||||
None** | - | - | - | - | - | - |
1 to 2 | 0.99 | 0.002 | 2.68 (1.44–5.00) | 2.44 | 0.021 | 11.46 (1.46–90.21) |
3 or more | 1.93 | <0.001 | 6.87 (3.71–12.75) | 3.33 | 0.003 | 27.84 (3.36–230.32) |
Χ24 (p value)*** | 1.62 | 0.805 | 1.92 | 0.751 | ||
Disordered stimulant use | ||||||
CA | ||||||
None** | - | - | - | - | - | - |
1–2 types | −0.24 | 0.828 | 0.79 (0.09–6.90) | 1.07 | 0.082 | 2.92 (0.87–9.78) |
3 or more types | −1.08 | 0.398 | 0.34 (0.03–4.27) | 0.47 | 0.432 | 1.60 (0.49–5.22) |
Minor stressors | ||||||
None** | - | - | - | **** | **** | **** |
1 to 2 | 0.94 | 0.297 | 2.57 (0.43–15.42) | −1.77 | 0.019 | 0.17 (0.04–0.74) |
3 or more | 2.62 | 0.003 | 13.78 (2.52–75.35) | **- | - | - |
Χ24 (p value)*** | 10.03 | 0.040 | 6.28 | 0.179 |
AOR (95% CI) = adjusted odds ratios (95% confidence intervals), adjusted for age, race, nativity
Reference category
Χ2 test of the interactions between CA and past year stressors in models for 12 month disorders
No-one in this category has the corresponding drug use disorder